Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

September 2, 2025
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
August 27, 2025
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 18, 2025
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
August 11, 2025
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
August 4, 2025
FibroGen to Report Second Quarter 2025 Financial Results
June 12, 2025
FibroGen Announces 1-for-25 Reverse Stock Split
June 9, 2025
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
May 12, 2025
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
May 5, 2025
FibroGen to Report First Quarter 2025 Financial Results
April 2, 2025
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 28, 2025
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
March 17, 2025
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
March 3, 2025
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Minimum 15 minutes delayed. Source: LSEG

Investor and Media Contact

Investors:
David DeLucia, CFA
Chief Financial Officer
[email protected]

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
ESG
Medical Information
Contact Us

Focus Areas

Our Expertise
Anemia
Pancreatic Cancer
Duchenne Muscular Dystrophy
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Notice

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2025 FibroGen, Inc.
350 Bay St, Ste 100 # 6009 San Francisco, CA 94133 USA